Frontlight ResearchEarly access
WithdrawnNo phase
A Study to Evaluate the Impact of 11-month Ticagrelor Monotherapy Following One-month DAPT After PCI
Key facts
- Who runs it
- Sino Medical Sciences Technology Inc.
- Trial code
- Status
- Withdrawn
- Started
- Sept 2021
- Ended
- Jul 2025
- Type of study
- Interventional
- Treatments tested
- HT Supreme
- Record updated
- 25 April 2024
- Why it stopped
- Withdrawn of the research project based on the company's decision
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Male or female patient ≥18 years of age
- Patient has chronic stable angina, acute coronary syndromes or silent ischemia
- Presence of one or more coronary artery stenoses of ≥50% (by visual assessment) in a native coronary artery (with or without prior stent/other device treatment) or in a saphenous venous or arterial bypass conduit suitable for coronary stent implantation
- The vessel should have a reference vessel diameter of at least 2.25 mm by visual assessment (no limitation on the number of treated lesions, vessels, or lesion length)
- Patient has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Ethical Committee and is willing to comply with all protocol-required (follow-up) evaluations
Who cannot take part
- Known intolerance to cobalt chromium, and medications such as sirolimus, aspirin, heparin, bivalirudin or P2Y12 inhibitors
- Planned major elective surgery requiring discontinuation of DAPT within 12 months of procedure
- Concurrent medical condition with a life expectancy of less than 3 years
- Total occlusion or thrombolysis in myocardial infarction(TIMI) flow 0, prior to wire crossing
- Active pathological bleeding
- History of intracranial haemorrhage; OCT exclusion criteria
- under 18 years of age
- Unable to sign written informed consent
- Patient is a woman who is pregnant or nursing
- Currently participating in another trial and not yet at its primary endpoint
- Left main lesion
- Severe tortuous, calcified or angulated coronary anatomy of the study vessel that in the opinion of the investigator would result in suboptimal imaging or excessive risk of complication from placement of an OCT catheter
About the trial
What the trial wants to find out
PIONEER IV CHINA is sought to investigate the safety and efficacy of 11-month ticagrelor monotherapy following one-month dual antiplatelet therapy (DAPT) after HT Supreme drug-eluting stent system at 12 months follow-up.
The group in the trial
- HT SupremeTreatment being tested
Device: HT Supreme ( R\&D by Sinomed, Tianjin, China) Drug: 11-month ticagrelor monotherapy following one-month dual antiplatelet therapy (DAPT) after HT Supreme drug-eluting stent system interventions
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Multi-center, Single-group Target Value Post-marketing Clinical Study to Evaluate the Safety and Effectiveness of the HT Supreme Drug-eluting Stent System in the Treatment of "Real-world" Patients With Coronary Heart Disease
- Record updated
- 25 April 2024